Search results
Results from the WOW.Com Content Network
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Will that trend continue in ...
Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. ... The following three players could be the best-performing pharma and biotech ...
In the third quarter, the company's revenue of $2.77 billion increased by 12% year over year, a strong performance for a biotech giant. The company's best CF treatment yet, Trikafta, accounted for ...
VRTX data by YCharts. 1. Vertex Pharmaceuticals. Vertex Pharmaceuticals is starting the year strong. On Jan. 30, the company announced that the U.S. Food and Drug Administration had approved ...
These longtime leading biotech stocks still have plenty of ... 2024 at 10:15 AM ... revenue increased by 6% year over year to $2.65 billion. And Vertex's top line will start growing faster soon ...
Top 9 Biotech ETFs for 2024 When assessing all angles of an investment, you want to make sure your money will be working for you, or at least predicted to do so. Here are a few recommendations for ...
Viking rose to stardom earlier this year after it released strong results from a phase 2 clinical trial for its leading anti-obesity candidate, VK2735. This candidate is still some distance away ...
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...